The Texas Department of State Health Services (DSHS) has expanded its newborn screening panel by adding four lysosomal disease tests in August. With these additions, the number of conditions screened for every baby born in Texas now stands at 59. Each infant is screened twice, resulting in approximately 800,000 specimens tested annually at the Texas Newborn Screening Laboratory.
Hearing loss and critical congenital heart disease are also checked as point-of-service tests, usually conducted by birthing facilities.
“Time is of the essence for many of these disorders, and immediate action and treatment may help prevent serious health complications,” said DSHS Commissioner Jennifer A. Shuford, MD, MPH. “Newborn screening plays a vital role in protecting these most vulnerable Texans by identifying early any potential medical conditions.”
Lysosomal diseases are rare genetic disorders that cause harmful substances to accumulate in cells and organs due to missing or malfunctioning enzymes. Early detection can allow for treatments that help manage symptoms and reduce damage to organs and tissues.
The newly included lysosomal diseases are Pompe Disease, Mucopolysaccharidosis Type I (MPS I), Mucopolysaccharidosis Type II (MPS II), and Infantile Krabbe Disease (KD). These diseases can lead to severe health issues or early death if not identified quickly. Incidence rates for each condition are about 1 per 100,000 births in Texas—equating to roughly four cases annually per disease—with Pompe Disease estimated slightly higher at up to ten cases per year.
To support this initiative, DSHS used grant funding from the Centers for Disease Control and Prevention as well as resources from the Newborn Screening Preservation Account established by state lawmakers in 2019. The department made several changes: modifying laboratory space and systems, installing new instruments, developing tests and screening algorithms, updating information management systems, and hiring additional staff for both laboratory work and clinical coordination.
Newborn screening involves collecting a heel stick blood sample from babies between 24 to 48 hours after birth; a second sample is taken when the infant is seven to fourteen days old. If results fall outside expected ranges, follow-up with healthcare providers begins immediately.
This year, state legislators authorized DSHS to use federal funds for building new laboratory space. Once operational, it will enable further newborn screening tests such as those for Duchenne Muscular Dystrophy.
Texas identifies around 1,000 newborns with life-threatening disorders each year through its screening program. The initiative began sixty years ago with testing for phenylketonuria—a major cause of intellectual disability at the time that could be managed if detected early.
“Time is of the essence for many of these disorders, and immediate action and treatment may help prevent serious health complications,” said DSHS Commissioner Jennifer A. Shuford, MD, MPH. “Newborn screening plays a vital role in protecting these most vulnerable Texans by identifying early any potential medical conditions.”
###
